Inventor · Fremont, CA, US

Haichun Huang

81Patents
22h-index
136Co-inventors
91Inventor score

Filing activity: Apr 7, 2003 → Jul 28, 2022

Most-cited inventions

PatentTitleAreaCited byStatus
US7943743B2 Human monoclonal antibodies to programmed death ligand 1 (PD-L1) Emerging Cross-Sectional Technologies 541 Active
US8779105B2 Monoclonal antibodies to programmed death 1 (PD-1) Emerging Cross-Sectional Technologies 204 Active
US8383796B2 Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1) Emerging Cross-Sectional Technologies 148 Active
US9084776B2 Methods for treating cancer using anti-PD-1 antibodies Emerging Cross-Sectional Technologies 134 Active
US9492540B2 Methods for treating cancer using anti-PD-1 antibodies Emerging Cross-Sectional Technologies 116 Active
US9358289B2 Methods for treating cancer using anti-PD-1 antibodies in combination with anti-CTLA-4 antibodies Emerging Cross-Sectional Technologies 112 Active
US9387247B2 Monoclonal antibodies to programmed death 1 (PD-1) Emerging Cross-Sectional Technologies 98 Active
US9492539B2 Monoclonal antibodies to Programmed Death 1 (PD-1) Emerging Cross-Sectional Technologies 96 Active
US9102725B2 Human monoclonal antibodies to programmed death ligand 1 (PD-L1) Emerging Cross-Sectional Technologies 90 Active
US9273135B2 Human monoclonal antibodies to programmed death ligand 1 (PD-L1) Emerging Cross-Sectional Technologies 77 Active
US7960515B2 Binding molecules to the human OX40 receptor Chemistry; Metallurgy 67 Active
US8106167B2 Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors Physics 52 Active
US8124738B2 Human monoclonal antibodies to CD70 Emerging Cross-Sectional Technologies 51 Active
US9580507B2 Human monoclonal antibodies to programmed death ligand 1 (PD-L1) Emerging Cross-Sectional Technologies 47 Active
US7601818B2 Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors Physics 44 Expired
US7795413B2 Nucleic acids encoding human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors Physics 33 Active
US9228016B2 Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof Physics 31 Active
US8236930B2 Binding molecules to the human OX40 receptor Chemistry; Metallurgy 31 Active
US9580505B2 Human monoclonal antibodies to programmed death ligand 1 (PD-L1) Emerging Cross-Sectional Technologies 31 Active
US9028824B2 Binding molecules to the human OX40 receptor Chemistry; Metallurgy 26 Active
US7438910B2 Therapeutic human anti-IL1-R1 monoclonal antibody Chemistry; Metallurgy 25 Expired
US7718776B2 Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors Chemistry; Metallurgy 23 Expired
US9683998B2 Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof Chemistry; Metallurgy 21 Active
US10441655B2 Monoclonal antibodies to programmed death 1 (PD-1) Emerging Cross-Sectional Technologies 21 Active
US9605080B2 Antibodies against CD73 Physics 19 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.